Phase 1 trial of olaparib with temozolomide in relapsed glioblastoma
| ISRCTN | ISRCTN47380065 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN47380065 |
| EudraCT/CTIS number | 2010-018615-15 |
| ClinicalTrials.gov number | NCT01390571 |
| Secondary identifying numbers | 10482 |
- Submission date
- 10/08/2011
- Registration date
- 10/08/2011
- Last edited
- 25/04/2019
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English Summary
Contact information
Ms Jane Peters
Scientific
Scientific
Drug Development Office
Angel Building
407 St. John Street
London
EC1V 4AD
United Kingdom
Study information
| Study design | Non-randomised; Interventional; Design type: Treatment |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Non randomised controlled trial |
| Study setting(s) | GP practice |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
| Scientific title | A Cancer Research UK Phase I trial of olaparib (AZD2281), an oral PARP Inhibitor, in combination with extended lowdose oral temozolomide in patients with relapsed glioblastoma |
| Study acronym | OPARATIC |
| Study hypothesis | This is the first combination study of olaparib with temozolomide and with olaparib in patients with glioblastoma. Stage 1 requires six patients to be treated with olaparib prior to recurrent resection surgery. Evidence of olaparib in tumour biopsy material combined with evidence of PARP inhibition and DCE and DW MRI will explore the permeability of the blood brain barrier to olaparib in patients with recurrent glioblastoma. Stage 2 involves a dose escalation of combination treatment with extended low dose temozolomide and olaparib to find the MTD in the same recurrent patient population post-resection. Ten further patients will then be treated at the combination MTD and will undergo funcional MRI. |
| Ethics approval(s) | First MREC, 28/04/2011, ref: 11/AL/0213 |
| Condition | Brain Tumour |
| Intervention | 1. DCE/DW MRI, Dual baseline and one post-administration DCE/DW MRI scans to observe the permeability of the blood brain barrier. 2. Administration of olaparib PARP inhibitor prior to surgery followed by combination treatment with low dose temozolomide in 42 day cycles |
| Intervention type | Other |
| Primary outcome measure | 1. Identification of combination MTD 2. Reporting of safety information at every patient visit and throughout the trial |
| Secondary outcome measures | 1. Demonstration of olaparib in tumour tissue 2. Resection |
| Overall study start date | 18/07/2011 |
| Overall study end date | 02/01/2017 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Upper age limit | 70 Years |
| Sex | Both |
| Target number of participants | Planned Sample Size: 28; UK Sample Size: 28 |
| Total final enrolment | 45 |
| Participant inclusion criteria | 1. Histological proven glioblastoma (World Health Organisation[WHO] Grade 4). 2. Radiological diagnosis of recurrent or progressive disease according to RANO criteria, which is suitable for palliative resection. 3. Patients should have enough resectable tumour tissue for sampling requirements in the opinion of the neurosurgeon. 4. Prior 1st line treatment with radical radiotherapy, or chemoradiation followed by adjuvant chemotherapy (no prior chemotherapy for recurrent disease is allowed). 5. Aged between 18 and 70 years. 6. Life expectancy > 12 weeks 7. WHO performance status of 02 8. Haematological and biochemical indices within the ranges shown below. These measurements must be performed within one week before the patient goes on study. Haemoglobin (Hb) = 9.0 g/dL Absolute neutrophil count (ANC) = 1.5 x 109/L Platelet count = 100 x 109/L Serum bilirubin = 1.5 x upper limit of normal (ULN) ALT or AST = 2.5 x ULN Either: Calculated creatinine clearance = 50 mL/min Or: Isotope clearance measurement = 50 mL/min (uncorrected) 9. Ability to swallow and retain oral medications. 10. Written (signed and dated) informed consent and be capable of cooperatingwith treatment, scans and followup |
| Participant exclusion criteria | 1. Radiotherapy, endocrine therapy or immunotherapy during the previous 12 weeks before treatment, or chemotherapy during the 4 weeks before treatment. 2. Any previous treatment with a PARP inhibitor, including olaparib. 3. Ongoing toxic manifestations of previous treatments. Exceptions to this are alopecia or Grade 1 toxicities, which in the opinion of the Investigator and the Drug Development Office (DDO) should not exclude the patient. 4. Change to systemic steroids dose within the five days prior to enrolment (ie. must be on a stable dose at time of enrolment). 5. Ability to become pregnant (or already pregnant or lactating). However, those female patients who have a negative serum or urine pregnancy test before enrolment and agree to use two highly effective forms of contraception (oral, injected or implanted hormonal contraception and condom, have a intrauterine device and condom, diaphragm with spermicidal gel and condom) for four weeks before entering the trial, during the trial and for six months afterwards are considered eligible. 6. Male patients with partners of childbearing potential (unless they agree to take measures not to father children by using one form of highly effective contraception [condom plus spermicide] during the trial and for six months afterwards). Men with pregnant or lactating partners should be advised to use barrier method contraception (for example, condom plus spermicidal gel) to prevent exposure to the foetus or neonate. 7. Major thoracic or abdominal surgery from which the patient has not yet recovered. 8. At high medical risk because of nonmalignant systemic disease including active uncontrolled infection. 9. Known to be serologically positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV). 10. Concurrent congestive heart failure, prior history of class III/ IV cardiac disease (New York Heart Association [NYHA] refer to Appendix 3), prior history of cardiac ischaemia or prior history of cardiac arrhythmia within the previous 12 months. 11. Patients with pacemakers, a history of previous heart surgery, any major surgery in the preceding six weeks, metal fragments in their eyes, shrapnel or bullet injuries are excluded (on the basis of their unsuitability to undergo MRI scans). Patients with metal implants or tattoos should be discussed with MRI staff. 12. Grand mal seizures occurring = 3 times per week over the past month. 13. Patients with gastrointestinal disorders likely to interfere with absorption of the study medication. 14. Patients taking drugs known to be potent inhibitors or inducers of CYP3A4 including phenytoin, carbamazepine and phenobarbitone which cannot be stopped for the duration of the trial. 15. Immunisations with live vaccines received within the previous four weeks (or expected to receive during the trial and up to at least six months after receiving last study treatment). Including BCG and yellow fever. 16. Known hypersensitivity to any of the components of olaparib. 17. Known hypersensitivity to temozolomide (TMZ), or to any of its components, or to dacarbazine (DTIC) (Stage 2 only). 18. Known lactose intolerance (Stage 2 only) 19. Is a participant or plans to participate in another interventional clinical study, whilst taking part in this Phase I study. Participation in an observational study would be acceptable. 20. Any other condition which in the Investigators opinion would not make the patient a good candidate for the clinical trial. |
| Recruitment start date | 18/07/2011 |
| Recruitment end date | 02/01/2017 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
Drug Development Office, Angel Building , 407 St. John Street
London
EC1V 4AD
United Kingdom
EC1V 4AD
United Kingdom
Sponsor information
Cancer Research UK
Charity
Charity
Drug Development Office, PO Box 123
London
WC2A 3PX
United Kingdom
"ROR" |
https://ror.org/054225q67 |
|---|
Funders
Funder type
Charity
Cancer Research UK
Private sector organisation / Other non-profit organizations
Private sector organisation / Other non-profit organizations
- Alternative name(s)
- CR_UK, Cancer Research UK - London, CRUK
- Location
- United Kingdom
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Plain English results | No | Yes | |||
| HRA research summary | 28/06/2023 | No | No |
Editorial Notes
25/04/2019: The following changes were made to the trial record:
1. Link to plain English results added to: Results (plain English).
2. The total final enrolment was added.
3. The recruitment end date was changed from 01/07/2014 to 02/01/2017.
4. The overall end date was changed from 01/07/2014 to 02/01/2017.
18/11/2016: No publications found in PubMed, verifying study status with principal investigator.
